News

  • OCTOBER 2020: FALL UPDATE As a result of the successful financing round of CHF 10 million in April 2020, the InnoMedica team was able to reach important milestones in the main projects Talidox and ...
  • April 2020: Capital increase with public offering Please find below the relevant investor documents (including subscription form). Information on InnoMedica and the projects TaliCoVax-19 (vaccination), Talidox (oncology) and Talineuren (neurology) can be found in the business documentation. Investor ...
  • March 2020: InnoMedica launches project for corona vaccination The corona pandemic is a major challenge for everyone. In this context, InnoMedica can contribute its expertise to the development of an urgently needed vaccine. InnoMedica has good contacts with ...
  • June 2019: Annual General Meeting 2019 The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2019. The Annual General Meeting will be held on Tuesday, June 25th  2019 at 04:30 pm (registration at 04:00 pm) in ...
  • May 2019: Talidox better tolerated than expected On May 14, 2019, the sixth patient was treated with Talidox at the Inselspital Bern. The dose of 40mg/m2 now reached already corresponds to the maximum dose originally planned in ...
  • April – May 2019: CAPITAL INCREASE WITH PUBLIC OFFERING Capital increase with public offering of 103,516 bearer shares / CHF 23,456,725.60 The subscription ends May 31st 2019. Share price is CHF 226.60 per new share (minimum 60 shares).   Visit us at an investor event in Bern, ...
  • January 2019: Resignations from the Board of Directors The two Board members Dr. Herbert Früh and Manuel Frick resigned from the Board of Directors of InnoMedica Holding AG as of mid-January 2019. Herbert Früh has been a member ...
  • December Update 2018 Thanks to the successful financing round of CHF 10.25 million in May 2018, the InnoMedica team reached an important milestone with Talidox with the start of the clinical trial and ...
  • November 2018: Start of the clinical trial with Talidox Swissmedic has approved the clinical study phase I with Talidox. After production met all pharmaceutical standards, InnoMedica’s quality assurance released Talidox for clinical use. Last Monday, November 12, 2018, the ...
  • June 2018: Annual General Meeting 2018 The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2018. The Annual General Meeting will be held on Tuesday, June 26th  2018 at 04:30 pm (doors open at 04:15 pm) ...
  • June 2018: New capital of CHF 10.25 million The 2018 capital increase was closed on May 31 with subscriptions in the amount of CHF 10.25 million. As in previous financing rounds, we were able to substantially expand our ...
  • March – May 2018: Capital increase with public offering Capital increase with public offering of 153,272 bearer shares / CHF 31,574,032 The subscription ends May 31st 2018. Share price is CHF 206 per new share (minimum 75 shares).   Visit us at an investor event ...
  • Update December 2017 Thanks to the successful financing round of CHF 7.7 million in May 2017, the InnoMedica team has achieved significant progress with Talidox in recent months and further developed a new ...
  • June 2017: Annual general meeting 2017 The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2017. The Annual General Meeting will be held on Tuesday, June 20th  2017 at 04:30 pm (doors open at 04:15 ...
  • March-May 2017: Capital increase with public offering Join our oncology-project: Capital increase with public offer of 75,000 bearer shares / CHF 7,706,250 The subscription ends May 31, 2017. Share price is CHF 102.75 per new share (minimum 150 shares). Visit us at ...
  • Fall term update 2016 Thanks to the successful financing round of CHF 3.3 million in May 2016, the InnoMedica team was able to further advance the Talidox project in the last few months and ...
  • Getting Talidox to the cancer patients InnoMedica has made a good start to the New Year and is getting Talidox at full speed into the clinics. InnoMedica and SAKK are ready for the registration of the clinical ...
  • June 2016: Annual general meeting 2016 The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2016. The Annual General Meeting will be held on Tuesday, June 21st  2016 at 04:30 pm (doors open at 04:15 ...
  • Talidox better than caelyx/doxil and free doxorubicin In the in vivo study of the Mario Negri Institute, the effect of different treatments on tumor size in mice was examined, whereby in addition to an untreated control group (black) our ...
  • March-May 2016: Capital increase with public offer Today chemotherapy remains the standard medicine for treating cancer. Yet treatment with this medicine means drugs interact with the entire body – causing intense side effects. Our medicine packages a ...
  • April 2016: Innomedica at swiss Biotech Day in Basel April 12th, 2016, InnoMedica will participate at the Swiss Biotech Day. We will present our project Talidox in the Analyst & Investor track with regard to capital increase beginning until ...
  • January 2016: Positive results from efficacy study After the promising results from biodistribution and pharmacokinetics in autumn 2015, data form the efficacy study by Mario Negri Institute can now be presented. In an in vivo study with five mice per ...
  • December 2015: CTI grant approved Together with the Adolphe Merkle Institute (AMI), InnoMedica has filed an application for research funding in the amount of CHF 350,000 at the Commission for Technology and Innovation (CTI) of ...
  • Fall Term Update 2015 Thanks to our successful financing round of CHF 1.3 million in May 2015, the InnoMedica team was able to achieve significant progress in several areas in the last few months ...
  • June 2015: Annual general meeting 2015 The Board of InnoMedica cordially invites all shareholders to attend the Annual General Meeting 2015. The Annual General Meeting will be held on Wednesday, June 24th  2015 at 04:30 pm (doors open at ...
  • May 2015: Capital increase successful The capital increase of InnoMedica was successfully completed on May 26, 2015 and achieved new capital of more than CHF 1.3 million at a share price of CHF 57.50. The response from ...
  • April 2015: Innomedica at Swiss Biotech Day in Basel April 14th, 2015, InnoMedica will participate at the Swiss Biotech Day. We will present our project Talidox in the Analyst & Investor track with regard to capital increase beginning on ...
  • March-May 2015: Capital increase with public offering Capital increase with public offering of 100,000 bearer shares / CHF 5,750,000 The subscription period lasts until 26th of May 2015. The subscription price per new share is CHF 57.50 (denomination min. 200 ...
  • January 2015: Innomedica now GMP certified by SwissMedic After inspection of the cleanroom end of November 2014, InnoMedica has now received approval by Swissmedic for the production and wholesale of pharmaceuticals for the next 5 years. This includes ...
  • December 2014: TV feature story about Talidox In October 2014, the TV channel of the french speaking part of switzerland RTS broadcasted about InnoMedica as part of a news report about the Marly Innovation Center. On 25 December 2014, ...
  • October 2014: Innomedica in the News on RTS A short TV-report of our production site in Marly shows InnoMedica’s clean room for production. Click here to view the clip.
  • September 2014: Innomedica at Sachs Forum in Basel InnoMedica presents itself and the project TLD-1 at the 14th Biotech in Europe Forum for Global Partnering & Investment of SACHS Associates on September 30st 2014 in Basel: short presentation by Jonas Zeller, direct exchange ...
  • Swissmedic: Talidox® – A known substance with Innovation In order to obtain certainty about the applicable regulatory requirements for the registration of TLD-1, InnoMedica has requested a Scientific Advice Meeting with Swissmedic. We are pleased to announce that Swissmedic ...
  • In vitro data: Talidox® shows similar cell killing activity compared to free doxorubicin The cell killing activity of 100 μg/ml doxorubicin was measured on human uterine sarcoma cells in vitro in a cytotoxicity study. The cytotoxic effect of 100 μg/ml free doxorubicin (Adriblastin) was compared ...
  • June 2014: Annual general meeting 2014 The Board of InnoMedica cordially invites all shareholders to attend the Annual General Meeting 2014. The Annual General Meeting will be held on Tuesday, June 24th  2014 at 04:15 pm (doors open at ...
  • April 2014: Innomedica at swiss Biotech Day 2014 InnoMedica presents itself and the project TLD-1 at the Swiss Biotech Day 2014 at the Kongresshaus in Zurich: short presentation by Jonas Zeller (Financial Controller), direct exchange with the team ...
  • February 2014: Oversubscribed – Capital increase successful The capital increase of InnoMedica by 49,000 shares / CHF 655’500 was successfully completed with oversubscription. We are very pleased with the interest in our company as well as our project ...
  • february 2014: Support from SAKK FEBRUARY 2014: SUPPORT FROM SAKK INNOMEDICA RECEIVES SUPPORT FROM THE SAKK InnoMedica and the Swiss Group for Clinical Cancer Research ( SAKK ) hope to gain from the development of new cancer ...
  • December 2013: Capital increase for current shareholders Notice to current shareholders concerning ongoing capital increase: Subscription offer of CHF 665,550 / 45,900 bearer shares The subscription period will last until 24 Februar 2014. The subscription price per new share ...
  • September 2013: Production and research laboratories The InnoMedica establishes the research and production site. For the production of preclinical and initial clinical batches research laboratories in Marly, Fribourg are rented and equipped with the laboratory devices. ...
  • June 2013: Capital increase successful In June 2013, InnoMedica was able to complete the Capital Increase approved at the Annual General successfully. The newly acquired capital in the amount of more than CHF 500,000 allows InnoMedica ...